

# Pharmaceutical innovation as a pillar of economic growth

**Pascal Apostolides**


*General Manager AbbVie*

**21<sup>st</sup> Health World Conference, Athens**

6 October 2022



# Healthcare: from a cost factor to a growth multiplier



Source: WifOR illustration, following Henke, Neumann, Schneider et al. (2010)

## Examples of growth multipliers:

### 1) Clinical research as a growth opportunity

R&D in Europe (2020, EFPIA) - € million			
Austria	283	Latvia	n.a
Belgium	4,964	Lithuania	n.a
Bulgaria	91	Malta	n.a
Croatia	40	Netherlands	642
Cyprus	85	Norway	126
Czech Rep.	72	Poland	431
Denmark	1,486	Portugal	90
Estonia	n.a	Romania	69
Finland	258	Russia	706
France	4,451	Slovakia	35
Germany	7,813	Slovenia	334
 Greece	102	Spain	1,161
Hungary	298	Sweden	1,104
Iceland	n.a	Switzerland	7,380
Ireland	305	Turkey	71
Italy	1,620	U.K.	5,639
<b>TOTAL</b>		<b>39,656</b>	

GR: potential for +400m€ increase in the investment from clinical trials



## Examples of growth multipliers:

### 2) Greek “goldmine of data”: attracting investments in RWD



██████████ to acquire ██████████ Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer

██████████ 15 February 2018

- ◆ Acquisition will bring together two companies committed to improving the lives of cancer patients through the evolving field of healthcare data and analytics
- ◆ The companies will leverage their combined expertise to advance the use of real-world evidence to set new industry standards for oncology research and development
- ◆ ██████████ to continue its operations as a separate legal entity

██████████ and ██████████ announced today that the two partners have signed a definitive agreement under which ██████████ will acquire all shares of ██████████ following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018.

██████████, a privately held healthcare technology and services company headquartered in New York City, US, is a market leader in oncology-specific electronic health record (EHR) software, as well as the curation and development of real-world evidence for cancer research. With its large network of community oncology practices and academic medical centers across the US, ██████████ has created a technology platform designed to learn from the experience of every patient.

# FINDATA



## Examples of growth multipliers:

### 3) Making space for innovation through the Pharmaceutical Innovation Fund



*The Innovation Fund is a smart filter that accomplishes 4 goals simultaneously*



#### 1. Early launch & reward of true innovation

Launch without CB burden for a limited period of time after HTA positive opinion but before Negotiation



#### 2. No extra CB burden for all medicines

Although this is a pro innovation policy proposal, it safeguards that there will not be any clawback burden for the rest of the products that are already registered in the positive list (on-patent, off-patent, generic and biosimilar medicines)



#### 3. Rationalization of the closed budget

If the input is rational, then the whole budget will become rational as well in the medium to long term



#### 4. Sufficient time to MoH for reforms without pressure

In order to establish an HTA Organization, Therapeutic Protocols and Patient Registries as well as to create the appropriate fiscal space for the new launches

abbvie